Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cholestech's lipid and liver function test launched in the US:

This article was originally published in Clinica

Executive Summary

Hayward, California-based Cholestech is rolling out its Lipid Profile ALT test cassette in the US after the FDA granted CLIA waived status for the product, a test for liver function. The device enables healthcare providers to test a patient's lipid profile and alanine aminotransferase (ALT) levels simultaneously, giving results within five minutes. ALT is the most common marker for liver damage. The test can be performed in the doctor's office lab with just a single fingerstick. It is designed to allow doctors to monitor the patient's use of certain drugs, particularly statins, though lipid and liver monitoring are recommended when using a variety of other prescription drugs. Tests are performed before treatment initiation to establish a baseline level and periodically thereafter to help determine the appropriate therapeutic course of action.

You may also be interested in...

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

EU GMP Annex I Proposal Would Maintain PUPSIT, Relax WFI Restrictions

The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts